Bodi Envi review

Bodi Envi publishes a flat $130/month NAD⁺ headline and names its care and pharmacy partners. Confirm the assigned NAD⁺ pharmacy, full charge and refill schedule before paying: the refund policy bars cancellation or refunds after medical review and prescription issuance, even though future plans can be canceled. Injected NAD⁺ has no controlled human outcome trials behind it.

Bodi Envi is a telehealth weight-loss practice founded by Ashley and Shaun Padgett, with compounded semaglutide and tirzepatide, micro-dose programs, ondansetron and brand-name weight-loss options alongside NAD⁺ injections. Its terms identify BODI ENVI, LLC as platform operator and Wasef Health, P.A. and affiliates for care; the FAQ and About page instead call the clinical group Wasef Health, PC. That legal-suffix discrepancy is unresolved. The site names Michael Wasef as medical director and VialsRx in Tomball, Texas as a pharmacy partner for personalized compounded programs. These are provider disclosures; individual assignments and credentials need confirmation.

An online questionnaire and secure chat are the usual path, with audio or video when required and ongoing provider messaging. The FAQ claims eligible patients in all 50 states; it does not establish NAD⁺ availability for every patient or state. The NAD⁺ page names VialsRx for personalized compounded programs, but confirm which pharmacy receives your prescription. Pharmacy associations for brand-name weight-loss products do not establish NAD⁺ fulfillment. The About page describes eligible adults without a numeric NAD⁺ age minimum. Required NAD⁺ labs, their cost, formulation, quantity and monitoring details are not published. Insurance is not required; any HSA/FSA reimbursement depends on eligibility.

NAD⁺ injections are advertised at a flat $130 per month, the same price at every dose, with an injection kit, provider support and no membership fee. The product offer includes free two-day shipping on orders of $100 or more; the general shipping policy separately says charges are calculated at checkout. Two days describes carrier transit after pharmacy departure, not time from intake. Thursday–Sunday orders are described as shipping the following Monday. Confirm the complete first charge, prescribed quantity and supply, standalone eligibility and renewal amount/date; refill notices do not establish the billing cadence.

Once medical review is complete and a prescription is issued, that order cannot be canceled or refunded. Future plans can be canceled, but the policy also uses order-placement, pharmacy-transmission and refill-label cutoffs; obtain the applicable deadline before authorizing payment. Applicants who do not qualify are refunded. There are no partial refunds on 3-, 6- or 12-month plans, which are not specifically tied to NAD⁺. Dispensing concerns must reach the pharmacy within 48 hours of delivery. Carrier-confirmed delivery is treated as fulfilled, with no free replacement for delivered-but-not-received orders; delay-based refunds are excluded.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. Bodi Envi carries a compounding disclaimer and describes U.S. 503A pharmacy fulfillment. Its NAD⁺ page names VialsRx for personalized compounded programs; confirm the dispenser assigned to your prescription. Compounded sterile products are not FDA-reviewed for purity and potency the way approved drugs are. On the evidence, the NAD⁺ product needs stating plainly. Injected NAD⁺ has no controlled human outcome trials supporting the energy, recovery or longevity claims the category runs on, and the single human intravenous study was a pharmacokinetic pilot that found infused NAD⁺ clears from plasma quickly. The NAD⁺ forms with human trial data are the oral precursors NR and NMN, which reliably raise blood NAD⁺ — a raised biomarker, not a demonstrated clinical outcome. A well-run practice selling an unproven product is still selling an unproven product. Individual results vary.